Treatment Innovations

Advancing Urological Diagnostics: Bright Uro’s Glean System Receives Pivotal FDA Clearance advancing-urological-diagnostics-bright-uros-glean-system-receives-pivotal-fda-clearance

Lina Hope May 9, 2026

The landscape of urological diagnostics is undergoing a significant transformation. Bright Uro, a California-based medical technology innovator,...

Pharma’s Aggressive 2026: A Multi-Billion Dollar M&A Resurgence pharmas-aggressive-2026-a-multi-billion-dollar-ma-resurgence

Evan Lee Salim May 9, 2026

The global pharmaceutical landscape is currently undergoing a transformative shift, marked by an aggressive return to dealmaking...

A Decade of Precision: How Functional NAMs are Transforming Cardiac Safety Assessment a-decade-of-precision-how-functional-nams-are-transforming-cardiac-safety-assessment

Azzam Bilal Chamdy May 8, 2026

The landscape of pharmaceutical safety assessment is undergoing a profound metamorphosis. For decades, the industry has relied...

Rivanna’s Accuro XV Secures FDA Clearance: A New Frontier in Point-of-Care Musculoskeletal Imaging rivannas-accuro-xv-secures-fda-clearance-a-new-frontier-in-point-of-care-musculoskeletal-imaging

Ammar Sabilarrohman May 8, 2026

In a major milestone for point-of-care diagnostics, Virginia-based medical technology innovator Rivanna has received US Food and...

Strategic Expansion: Angelini Pharma to Acquire Catalyst Pharmaceuticals in $4.1 Billion Neuroscience Powerplay strategic-expansion-angelini-pharma-to-acquire-catalyst-pharmaceuticals-in-4-1-billion-neuroscience-powerplay

Nila Kartika Wati September 9, 2025

By Gwendolyn Wu Published May 7, 2026 In a move that signals a significant shift in the...

From Spreadsheets to Strategy: How AI is Overhauling the $5.9 Million Clinical Data Bottleneck from-spreadsheets-to-strategy-how-ai-is-overhauling-the-5-9-million-clinical-data-bottleneck

Pevita Pearce August 4, 2025

In the high-stakes world of pharmaceutical development, where a single Phase 3 clinical trial can represent billions...

You may have missed